×
TNF Pharmaceuticals EBIT 2012-2024 | TNFA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
TNF Pharmaceuticals ebit from 2012 to 2024. Ebit can be defined as earnings before interest and taxes.
View More
TNF Pharmaceuticals EBIT 2012-2024 | TNFA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
TNF Pharmaceuticals ebit from 2012 to 2024. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$78.6B
Takeda Pharmaceutical (TAK)
$44.1B
Merck (MKKGY)
$21.2B
Astellas Pharma (ALPMY)
$20.4B
Sandoz Group AG (SDZNY)
$19.7B
United Therapeutics (UTHR)
$18B
Summit Therapeutics (SMMT)
$15.6B
Neurocrine Biosciences (NBIX)
$12.6B
Shionogi (SGIOY)
$12.5B
Catalent (CTLT)
$10.9B
Madrigal Pharmaceuticals (MDGL)
$7.7B
Jazz Pharmaceuticals (JAZZ)
$7.4B
Orion OYJ (ORINY)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.1B
Corcept Therapeutics (CORT)
$5.7B
Crinetics Pharmaceuticals (CRNX)
$4.8B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$2.9B
Catalyst Pharmaceuticals (CPRX)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
Soleno Therapeutics (SLNO)
$2.5B
NewAmsterdam Pharma (NAMS)
$2B
Recursion Pharmaceuticals (RXRX)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Harrow (HROW)
$1.8B
Ocular Therapeutix (OCUL)
$1.7B
Xencor (XNCR)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
ARS Pharmaceuticals (SPRY)
$1.6B